By analogy with these findings, very recently, fulvestrant treatment was reported to down-regulate the progesterone receptor levels, monitored by PET in STAT1-deficient mammary tumors in mice [50], reflecting the response to endocrine therapy. This evidence concerns the gene PGR and breast cancer.